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OBJECTIVES We sought to determine whether the cardiac renin-angiotensin system (RAS) is activated in
human aortic valve disease depending on left ventricular function, and we analyzed the
concomitant regulation of the extracellular matrix components.
BACKGROUND In animal models with pressure or volume load, activation of the cardiac RAS increases
fibrosis. In human aortic valve disease, the ventricular collagen protein content is increased,
but only scarce data on the activation state of the cardiac RAS and its effects on collagen and
fibronectin messenger ribonucleic acid (mRNA) are available.
METHODS In left ventricular biopsies from patients with aortic valve stenosis (AS) and aortic valve
regurgitation and from control subjects, we quantitated mRNAs for angiotensin-converting
enzyme (ACE), chymase, transforming growth factor-beta1 (TGF-beta1), collagen I,
collagen III and fibronectin by reverse-transcription polymerase chain reaction. Proteins were
localized by immunohistochemistry; ACE activity was determined by high performance
liquid chromatography; and TGF-beta protein by quantitative enzyme immunoassay.
RESULTS Protein, ACE and TGF-beta1 mRNA were significantly increased in patients with AS and
AR (1.5- to 2.1-fold) and correlated with each other. The increase occurred also in patients
with normal systolic function. Collagen I and III and fibronectin mRNAs were both
upregulated about twofold in patients with AS and AR. In AS, collagen and fibronectin
mRNA expression levels were positively correlated with left ventricular end-diastolic pressure
and inversely with left ventricular ejection fraction (LVEF).
CONCLUSIONS In human hearts, pressure and volume overload increases cardiac ACE and TGF-beta1 in the
early stages. This activation of the cardiac RAS may contribute to the observed increase in
collagen I and III and fibronectin mRNA expression. The increase in extracellular matrix
already exists in patients with a normal LVEF, and it increases with functional impairment.
(J Am Coll Cardiol 2001;37:1443–9) © 2001 by the American College of Cardiology
Myocardial fibrosis, characterized by an elevation of myo-
cardial collagen and fibronectin content, appears early in
animal models of mechanical overload and increases further
during the transition from hypertrophy to heart failure
(1–3). Increased myocardial angiotensin-converting enzyme
(ACE) activity suggests that fibrosis is due to activation of
the cardiac renin-angiotensin system (RAS) (4–8). Angio-
tensin II induces transforming growth factor-beta1 (TGF-
beta1), which increases collagen synthesis in cell culture and
in in vivo models (9–12). In several models, an early
increase in TGF-beta1 messenger ribonucleic acid (mRNA)
precedes the increase in collagen and fibronectin mRNA,
suggesting that TGF-beta1 mediates the profibrotic effects
of angiotensin II (13,14).
Increased myocardial fibrosis has also been observed in
human hearts with aortic valve disease and contributes
significantly to an increase in diastolic stiffness and impair-
ment of systolic function with progressive disease (15–18).
Morphometric studies showed an increased collagen protein
content, which was slowly reversible after mechanical un-
loading (16,18,19). In the human heart, it is not known
whether this increase in collagen occurs at the mRNA level
or whether it is mainly determined by post-translation
regulation (i.e., by an altered turnover rate) (20). In human
end-stage heart failure, regulation of collagen synthesis at
the mRNA level and a significant change in the collagen I
to III mRNA ratio were reported, which suggests an
independent regulation of these two genes, with potential
functional consequences (21,22).
Expression and activity of ACE are increased in human
heart failure, in cardiomyopathy (23) and near an infarct
scar (24). Because ACE mRNA or activity and TGF-beta1
have not yet been measured in mechanically loaded human
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hearts with maintained systolic function, it remains debat-
able whether mechanical overload by itself induces an
activation of the human cardiac RAS. In addition to ACE,
human heart chymase, which is mainly expressed in mac-
rophages, and thus locally separated from myocytes and
fibroblasts, is able to form angiotensin II in the human heart
and to activate fibrotic processes (25,26).
In this study, we investigated whether ACE and TGF-
beta1 are increased in the myocardium of patients with
aortic valve disease and whether their regulation is associ-
ated with an increase in collagen I and III and fibronectin
mRNA and with cardiac function.
METHODS
Patients. Myocardial samples from 17 patients with pre-
dominant aortic valve stenosis (AS) (AS group I [AS-I])
and 6 patients with predominant aortic valve regurgitation
(AR) were analyzed for their mRNA content. In 14 of these
patients with AS and 4 with AR, enough material was
available to determine myocardial ACE activity. In a second
series, eight new patients with AS (AS group II [AS-II])
and six control subjects were analyzed for TGF-beta1
protein (Table 1). Tissue from the left ventricular part of the
septum was obtained during cardiac surgery and frozen
immediately on dry ice. For a subgroup analysis, the 17
patients in the AS-I group were classified into those with a
normal (.55%) left ventricular ejection fraction (LVEF)
(62 6 4%, n 5 8, left ventricular end-diastolic pressure
[LVEDP] 12 6 2 mm Hg, aortic valve pressure gradient
[dp] 86 6 11 mm Hg) and into those with impaired
(,55%) LVEF (38 6 2%, n 5 9, LVEDP 22 6 3 mm Hg
and aortic valve dp 69 6 9 mm Hg). Seven patients without
aortic valve disease and normal systolic cardiac function
served as the control subjects (mitral valve stenosis [n 5 3],
explanted hearts [n 5 4] and unused donor heart [n 5 1]).
Written, informed consent was obtained from all patients.
The study followed the rules for investigation of human
subjects, as defined in the Declaration of Helsinki.
Preparation of RNA and quantitation by reverse-
transcription polymerase chain reaction (RT-PCR). To-
tal RNA preparation, complete deoxyribonuclease (DNase)
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
AR 5 aortic (valve) regurgitation
AS 5 aortic (valve) stenosis
GAPDH 5 glyceraldehyde-3-phosphate dehydrogenase
hHC 5 human heart chymase
LVEDP 5 left ventricular end-diastolic pressure
LVEF 5 left ventricular ejection fraction
mRNA 5 messenger ribonucleic acid
PDH 5 pyruvic dehydrogenase
RAS 5 renin-angiotensin system
RT-PCR 5 reverse-transcription polymerase chain
reaction
TGF-beta1 5 transforming growth factor-beta1
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digestion and reverse transcription were performed as de-
scribed previously (27–31). The mRNA levels for ACE,
human heart chymase (hHC), TGF-beta1, collagen I and III,
fibronectin and the reference genes glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and pyruvic dehydroge-
nase (PDH) were determined by using a “hot start” PCR
procedure that was validated with respect to the reproducibility
and linearity within the measuring range and had comparable
efficacies of ;1.9. The PCRs were run in duplicate, and the
products were quantitated by reverse-phase high performance
liquid chromatography, as previously described (30). The
reproducibility (day to day variance ,3%) and linearity (.50-
fold range) of the procedure were tested by separation of a
plasmid standard (PBR 322-Hae III digest, Sigma, Aldrich,
Muenchen, Germany). The variance of the PCR/high perfor-
mance liquid chromatography procedure alone was determined
by repeated analysis of seven samples and was ,5% in this
study.
To correct for potential variances between samples in
mRNA extraction and RT efficacy and for variances in PCR
pipetting, the mRNA content of ACE, TGF-beta1, collagen I
and III and fibronectin was related to the mRNA content of
the stably expressed reference genes GAPDH and PDH from
the same aliquot. The expression of GAPDH and PDH
mRNA in our samples was identical in the three patient groups
and correlated significantly with each other (r 5 0.91, p ,
0.001, data not shown). In general, GAPDH was used as a
reference gene. The TGF-beta1 mRNA content was related to
PDH mRNA, because the optimized RT and PCR conditions
for these two genes were almost identical, but they were
different for GAPDH.
Activity of ACE and TGF-beta1 ELISA. Myocardial
ACE activity was determined from 15 to 30 mg of tissue, by
the formation of angiotensin II from angiotensin I in the
presence or absence of 0.1 mmol/liter of captopril. The
angiotensin II formed is measured by high performance
liquid chromatography (25). Activity of ACE is calculated
in nmol/liter of angiotensin II per min per g wet weight.
The coefficient of variance was 4%.
To estimate the total (latent and active) TGF-beta1
protein content in the myocardial samples (in triplicates),
we used a quantitative sandwich enzyme immunoassay
technique (Quantikine, R&D Systems, Minneapolis, Min-
nesota), according to the manufacturer’s protocol, as de-
scribed previously (32).
Immunohistochemistry. Cryosections of tissue samples
were air dried and fixed with acetone. The following
antibodies were used for the staining of actin: collagen I
(mouse, dilution 1:50 [Sigma-Aldrich]), fibronectin (rabbit,
dilution 1:100 [ICN Biomedicals, Aurora, Ohio]), TGF-
beta1 (mouse, dilution 1:100 [R&D Systems, Minneapolis,
Minnesota]), ACE (mouse, dilution 1:1000 [Chemicon,
Temecula, California]) and phalloidin (dilution 1:000 [Sig-
ma]). Incubation with phosphate-buffered saline instead of
the first antibody served as a negative control study. Nuclei
were stained with actinomycin D (Molecular Probes, Eu-
gene, Oregon). The sections were viewed in a confocal laser
microscope (Leica, Salms, Germany). The optical confocal
sections taken through the depth of tissue samples at 0.5- to
1.0 mm intervals were viewed and photographed individu-
ally, or were superimposed for reconstruction in a three-
dimensional mode using a Silicon Graphics Indy work
station and three-dimensional multichannel image process-
ing software (Bitplane, Zurich, Switzerland).
Statistics. Statistics were calculated with the SPSS soft-
ware, version 10.0. Results are expressed as the mean value
and SEM. The Mann-Whitney U test was used to calculate
differences between the groups. Analysis of variance correc-
tions were used for multiple testing. In the case of equal
variances, the Bonferroni procedure was used, and in the
case of unequal variances, the Tamhane-T2 procedure was
used, as provided by the SPSS program. A corrected p value
,0.05 was considered to be statistically significant. Regres-
sion analysis was prespecified for the whole group of
patients to detect correlations between mRNA expression
levels for genes encoding matrix proteins, ACE and TGF-
beta1 and for the patients with AS whenever hemodynamic
variables were included. Pearson’s correlation coefficients
were calculated with SPSS for Windows.
RESULTS
Regulation of myocardial ACE, TGF-beta1 and hHC.
Expression of ACE mRNA was significantly increased in
patients with AS (1.6-fold, p , 0.05). This includes the
subgroup with normal left ventricular function (LVEF
.55%, n 5 8, 1.7-fold increase, p , 0.05) (Figs. 1, 2).
Expression of ACE mRNA was also significantly increased
in patients with AR (1.8-fold, p , 0.01). Activity of ACE
was increased in patients with AS (39.7 6 5 nmol/min/g
wet weight; n 5 14; p 5 0.05) and in the whole group of
patients with aortic valve disease versus the control subjects
(43.1 6 5.2 vs. 29.8 6 0.6 nmol/min per g wet weight; p 5
0.01). Immunohistochemistry confirmed an increase in
ACE expression in capillaries as well as in myocytes (Fig. 3,
A and B, row IV). Chymase mRNA was downregulated in
patients with AS to about one-third of the control levels
(p , 0.001), and comparably in patients with normal or
impaired systolic function (Fig. 2), whereas patients with
AR had unchanged mean values, together with a very large
variability (data not shown).
The mRNA of TGF-beta1 was significantly raised in
patients with AS (1.5-fold, p , 0.05), including the
subgroup with normal LVEF (n 5 8, 1.4-fold, p , 0.01)
(Fig. 1, 2). In samples from patients with AR, TGF-beta1
mRNA was also significantly increased (1.6-fold, p , 0.01)
(Fig. 1). The TGF-beta1 protein was measured by ELISA
and was significantly upregulated in patients with AS as
compared with control subjects (1,230 6 230 vs. 623.3 6
62 pg/mg protein, p , 0.02). Immunohistochemistry con-
firmed an increase in TGF-beta1 expression in the hyper-
trophied myocardium (Fig. 2, A and B, row II ).
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Upregulation of collagen I and III and fibronectin. The
collagen I and III and fibronectin mRNA expression levels
were significantly increased in AS (2.1-fold, p , 0.001;
1.7-fold, p , 0.05; 2.3-fold, p , 0.005). Collagen I mRNA
was also increased in the small subgroup of patients with AS
and normal left ventricular function (LVEF .55%, n 5 8,
1.7-fold, p , 0.05) (Fig. 1, 2). In the patients with AR,
increases in collagen I and III and fibronectin mRNA were
found (2.4-, 1.9- and 2.6-fold, respectively), which was com-
parable to the changes observed in patients with AS; however,
there was more interindividual variability in the former group
(p 5 NS; data not shown) (Fig. 1). The upregulation of
collagen and fibronectin protein was confirmed by immuno-
histochemistry (Fig. 3, A and B, rows I and III).
Relation between gene expression and hemodynamic
variables. First, regression analysis of the whole group of
patients and control subjects was undertaken to detect whether
the observed changes in gene expression were correlated with
each other. A significant correlation was found between ACE
mRNA and TGF-beta1 mRNA (r 5 0.55, p , 0.002). The
increases in the genes’ expression for collagen (Col) I and III
and fibronectin (Fn) were closely correlated with each other
(Col I/III: r 5 0.89; Col I/Fn: r 5 0.89; Col III/Fn: r 5 0.88;
all p , 0.0001, data not shown).
In a second step, in the subgroup of patients with AS, we
analyzed whether a significant correlation between gene
expression and hemodynamic variables could be established.
Significant positive correlations between collagen I and III
and fibronectin gene expression and LVEDP (LVEDP/Col
I: r 5 0.60, p , 0.05; LVEDP/Col III: r 5 0.61, p , 0.05;
LVEDP/Fn: r 5 0.53, p 5 0.05) were observed. Significant
inverse correlations existed between collagen I and fibronec-
tin gene expression and left ventricular systolic function
(LVEF/Col I: r 5 20.56, p , 0.05; LVEF/Fn: r 5 20.53,
p , 0.01; data not shown).
Therapy with ACE inhibitors. The ACE inhibitors ena-
lapril (10 mg/day; n 5 1), ramipril (5 mg/day; n 5 1),
lisinopril (10 mg/day; n 5 1) and captopril (12.5 mg/day;
n 5 2) were used in five patients in the AS-I group to treat
hypertension and heart failure. Accordingly, patients treated
Figure 1. Expression of ACE, TGF-beta1 and collagen I mRNA in patients with AS and AR. Bar graphs show ACE/GAPDH (left); TGF-beta1/PDH
(middle); and collagen (Col) I/GAPDH (right) expression in control hearts (Con), patients with AS and patients with AR. The expression of ACE mRNA
and TGF-beta1 mRNA was significantly increased in AR and AS. The collagen I mRNA was significantly increased in AS and was elevated in AR, without
reaching the level of statistical significance. The mean values 6 SEM are presented, and analysis of variance was performed, with the Bonferroni-corrected
(Tamhane-T2 procedure) p values indicated. n.s. 5 not significant.
Figure 2. Expression of ACE, hHC, TGF-beta1, collagen I and III and fibronectin mRNA in patients with AS and normal or impaired LVEF. The bar
graph shows ACE/GAPDH; chymase/GAPDH; TGF-beta1/PDH; collagen (Col) I/GAPDH; collagen III/GAPDH; and fibronectin (Fn)/GAPDH
expression in patients with AS and normal or impaired LVEF (.55%, ,55%, respectively). The ACE mRNA, hHC, TGF-beta1 and collagen I mRNA
expression was significantly altered in both groups, whereas the increase in collagen III and fibronectin mRNA only reached statistical significance in
patients with AS and impaired LVEF. The mean values 6 SEM are presented, and analysis of variance was performed, with the Bonferroni-corrected
(Tamhane-T2 procedure) p values indicated. n.s. 5 not significant. *p , 0.05. **p , 0.01.
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Figure 3. Immunofluorescence for collagen, fibronectin, ACE and TGF-beta1. Row I (top) 5 immunofluorescence for collagen I (green, nuclei are red).
(A) Normal myocardium with fine septa surrounding the myocytes and capillaries. (B) In hypertrophied myocardium, the amount of collagen I between
the myocytes is increased. Row II 5 immunofluorescence for TGF-beta1 (green, myocytes are red by phalloidin). (A) In normal myocardium, only a few
cells in the interstitium are positive for TGF-beta1. (B) In hypertrophied myocardium, numerous structures contain TGF-beta1 as fine granules. Row III 5
immunofluorescence for fibronectin (green, nuclei are red). (A) Normal myocardium shows fine layers of fibronectin between the myocytes, corresponding
to labeling for collagen I. (B) In hypertrophied myocardium, the amount of fibronectin is greatly increased. In three-dimensional reconstruction in the
confocal microscope, the myocytes are blue. Row IV (bottom) 5 immunofluorescence for ACE (green, nuclei are red). (A) Only a few small capillaries
are positive for ACE in normal myocardium. (B) In hypertrophied myocardium, labeling for ACE is more prominent.
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with ACE inhibitors had more unfavorable hemodynamic
characteristics as compared with patients not treated with
ACE inhibitors (LVEF 42.4 6 6.0% vs. 52.5 6 4.3%;
LVEDP 22.5 6 4.0 vs. 13.5 6 1.9 mm Hg; mean
pulmonary artery pressure 21.0 6 0.8 vs. 13.5 6
0.3 mm Hg; p , 0.05 for all). Therapy with ACE inhibitors
was associated with reduced myocardial ACE activity (pa-
tients with AS treated with ACE inhibitors: 23.3 6 4.6
mmol/min/g wet weight; patients with AS not treated with
ACE inhibitors: 47.9 6 21.4 mmol/min/g wet weight; p 5
0.009) and a tendency toward a reduced ACE mRNA
content, but no other significant changes in gene expression.
DISCUSSION
We report an increase in the expression of ACE and TGF-
beta1 in human hearts with AS and AR. The increases in ACE
and TGF-beta1 mRNA correlate with each other and are
accompanied by an increase in ACE activity and TGF-beta1
protein. The increased expression of the RAS components was
accompanied by upregulation of collagen I and III and fi-
bronectin at the mRNA level. Together with our in vitro
studies of human hearts (32), the data suggest that activation of
the cardiac RAS occurs early in human aortic valve disease and
contributes to the development of myocardial fibrosis. Signif-
icant correlations were found between the expression of colla-
gen I and III and fibronectin mRNA and hemodynamic
variables in patients with AS, which points to a clinical
relevance of the observed changes.
Activation of the cardiac RAS in human aortic disease.
Activation of the cardiac renin-angiotensin-aldosterone sys-
tem contributes to cardiac fibrosis in a number of experi-
mental conditions, and ACE inhibitors prolong survival and
delay the transition to heart failure in rats with AS (5–
7,10,33–35). Our data show, for the first time, to our
knowledge, that the cardiac RAS and its mediator TGF-
beta1 are also activated in human hearts with AS and AR,
and that the increase in ACE and TGF-beta1 occurs in
hearts with normal systolic function. This supports, at a
molecular level, the clinical observation that angiotensin II
is involved in the pathogenesis of cardiac dysfunction in
mechanically overloaded human hearts (36).
Angiotensin II activates the synthesis and secretion of
TGF-beta1 in in vitro and in vivo models (9,11–14). We
found a significant upregulation of TGF-beta1 mRNA in
human AS with normal and impaired systolic function, as
well as in AR, and it was correlated to the upregulation in
ACE mRNA. Because TGF-beta1 mRNA content is not
regulated only by the activation of the RAS, but also by
direct mechanical load and tissue catecholamines (37), and
because the number of individuals studied was small and
they had a broad range of clinical conditions, a better
correlation than that observed may not be expected. In our
previous in vitro studies in isolated human cardiac fibro-
blasts and human atrial tissue samples, TGF-beta1 upregu-
lated collagen I and III mRNA (32).
The observed downregulation of hHC mRNA in AS is in
agreement with previous large animal experiments where
right ventricular hypertrophy was associated with significant
decreases of right ventricular chymase expression and in-
creases in ACE expression (38). We found, in as yet
unpublished studies, that the expression of chymase was
linked to the number of mast cells and expression levels of
cytokines in the human heart, and both seem to be reduced
in AS (unpublished data by Fielitz et al., 2000).
Collagen and fibronectin gene regulation in myocardial
hypertrophy. The upregulation of myocardial collagen
mRNA also occurred in patients with AS with normal systolic
function (i.e., in the compensated state of mechanical loading)
and was increased in patients with more severely compromised
cardiac function. This suggests a contribution to the transition
from pure hypertrophy to cardiac failure. Similar observations
have been made in animal models (3,39). The significant
positive correlation between collagen I and III and fibronectin
and LVEDP confirmed the available evidence that a rise in
collagen concentration is associated with abnormal diastolic
stiffness and diastolic dysfunction (2,40). A significant negative
association existed between collagen and fibronectin mRNA
and LVEF in AS and supports the notion that an increased
myocardial collagen content is also associated with systolic
dysfunction, as well as diastolic dysfunction.
The upregulations of collagen I and III and fibronectin
mRNAs correlate closely with each other in aortic valve
disease. This is in contrast with findings in human cardio-
myopathy, where significant alterations in the relative
amounts of collagen I and III mRNAs and isoforms, and
thus different regulation of both genes, are reported (21,22).
Therapy with ACE inhibitors. Medical therapy with
ACE inhibitors was used in some patients to treat hyper-
tension or heart failure. Inclusion of the ACE inhibitor-
treated patients in the analysis was regarded as justified,
because they did not differ from the rest of the group in
terms of the expression of any gene except ACE itself,
which represents a known effect of ACE inhibitor therapy
on ACE gene expression (41). Because ACE inhibitors
were not administered in a controlled manner, but were
more frequently used in patients with more severe hemo-
dynamic impairment, we cannot judge their specific effects
on myocardial gene expression from our patient sample.
Study limitations. This study started from the large body
of published data that testifies to the increase in fibrous
tissue in collagen and fibronectin protein in human aortic
valve disease (2,15,16,18,19). The material was limited and
preferentially used for mRNA quantitation. Because of the
shortage of material, measurements of ACE activity and
TGF-beta1 protein content and immunohistochemistry
could only be performed in subgroups.
Reprint requests and correspondence: Prof. Dr. Regitz-
Zagrosek, Deutsches Herzzentrum Berlin, Augustenburger Platz
1, 13353 Berlin, Germany. E-mail: zagrosek@dhzb.de.
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